Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Locana, a start-up that is developing CRISPR-based therapies that target and edit RNA, has raised $55 million in series A financing. The company was cofounded by University of California, San Diego, scientist Gene Yeo in 2016 after his lab reprogrammed CRISPR-Cas9 to cut RNA instead of DNA. That strategy could be used to destroy disease-causing RNA transcripts in conditions like amyotrophic lateral sclerosis and Huntington’s disease. Yeo says Locana is now looking beyond CRISPR for RNA-binding proteins that could be engineered for making RNA-editing therapies.
This article has been sent to the following recipient: